S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX

• Gili Kenet,
• Beatrice Nolan,
• Bulent Zulfikar,
• Bulent Antmen,
• Guy Young,
• Jiarui Chi,
• Marion Afonso,
• Viridiana Cano,
• Christian Sussebach,
• Shauna Andersson,
• Kaan Kavakli

Affiliations

Gili Kenet

1 Tel Aviv University, The National Hemophilia Centre, The Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Aviv, Israel

Beatrice Nolan

2 Children’s Health Ireland at Crumlin, Dublin, Ireland

Bulent Zulfikar

3 Istanbul University Oncology Institute, Division of Pediatric Hematology-Oncology, Istanbul, Turkey

Bulent Antmen

4 Acibadem University, Adana Hospital, Department of Pediatric Hematology/Oncology and Bone Marrow Transplantation Unit, Faculty of Medicine,, Adana, Turkey

Guy Young

5 Hemostasis and Thrombosis Center, Cancer and Blood Diseases Institute, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, LA, CA, United States

Jiarui Chi

6 Sanofi, Bridgewater, New Jersey, United States

Marion Afonso

7 Sanofi, Chilly-Mazarin, France

Viridiana Cano

8 Sanofi, Cambridge, United States

Christian Sussebach

9 Sanofi, Frankfurt am Main, Germany

Shauna Andersson

8 Sanofi, Cambridge, United States

Kaan Kavakli

10 Kaan Department of Haematology, Ege University Faculty of Medicine, Children’s Hospital, Izmir, Turkey